Liquid Biopsy in EGFR-Mutated Advanced NSCLC from T790M to MET Amplification: Clinical Implications and Possibilities in the Resistance Setting

被引：0
|
作者：
Della Gravara, Luigi [1 ]
Battiloro, Ciro [2 ]
Avellino, Aniello [2 ]
Caputo, Francesca [3 ]
D'Aniello, Carmine [3 ]
Rocco, Danilo [2 ]
机构：
[1] Univ Campania Luigi Vanvitelli, Dept Precis Med, I-80138 Naples, Italy
[2] AORN Colli Monaldi, Dept Pulm Oncol, I-80131 Naples, Italy
[3] AORN Colli Monaldi, Dept Med Oncol, I-80131 Naples, Italy
来源：
JOURNAL OF MOLECULAR PATHOLOGY | 2023年 / 4卷 / 02期
关键词：
NSCLC; EGFR; MET; osimertinib; liquid biopsy; NGS; cfDNA; ctDNA; CELL LUNG-CANCER; TREATMENT ALGORITHM; OSIMERTINIB; THERAPY; C797S; 1ST;
D O I：
10.3390/jmp4020009
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
According to the ESMO and ASCO clinical guidelines, the main role of liquid biopsy in EGFR+ advanced NSCLC patients is represented by T790M detection after erlotinib/gefitinib/afatinib progression. However, the general international expert consensus regards osimertinib as the preferred upfront treatment in this setting; therefore, this role has been scaled back in recent years. As of today, liquid biopsy has no ASCO or ESMO recommendation following first-line osimertinib; in the same vein, no targeted therapy has received ASCO or ESMO recommendation following post upfront Osimertinib progression. However, this standard could change in the near future. Therefore, adopting a clinical point of view, this paper aims to provide a comprehensive review on the previous, the current and the possible future role of liquid biopsy in the framework of the diagnostic-therapeutic algorithm of EGFR+ advanced NSCLC.
引用
收藏
页码：81 / 88
页数：8
相关论文
共 50 条
  • [1] Clinical implications of the T790M mutation in disease characteristics and treatment response in patients with EGFR-mutated NSCLC.
    Gaut, Daria
    Sim, Myung Shin
    Wolf, Brian R.
    Abarca, Phillip A.
    Carroll, James M.
    Goldman, Jonathan Wade
    Garon, Edward B.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients
    Kuiper, J. L.
    Heideman, D. A. M.
    Thunnissen, E.
    Paul, M. A.
    van Wijk, A. W.
    Postmus, P. E.
    Smit, E. F.
    LUNG CANCER, 2014, 85 (01) : 19 - 24
  • [3] Heterogeneous Resistance Mechanisms in Rebiopsies from EGFR-Mutated NSCLC: Transformation to SCLC; FGFR3 and T790M Mutations
    Urbanska, E.
    Grauslund, M.
    Melchior, L.
    Sorensen, J. B.
    Santoni-Rugiu, E.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2203 - S2203
  • [4] Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib
    Oya, Yuko
    Yoshida, Tatsuya
    Asada, Kazuhiro
    Oguri, Tetsuya
    Inui, Naoki
    Morikawa, Sayako
    Ito, Kentaro
    Kimura, Tomoki
    Kunii, Eiji
    Matsui, Takashi
    Kubo, Akihito
    Kato, Tatsuo
    Abe, Takashi
    Tsuda, Takeshi
    Hida, Toyoaki
    BMC CANCER, 2021, 21 (01)
  • [5] Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib
    Yuko Oya
    Tatsuya Yoshida
    Kazuhiro Asada
    Tetsuya Oguri
    Naoki Inui
    Sayako Morikawa
    Kentaro Ito
    Tomoki Kimura
    Eiji Kunii
    Takashi Matsui
    Akihito Kubo
    Tatsuo Kato
    Takashi Abe
    Takeshi Tsuda
    Toyoaki Hida
    BMC Cancer, 21
  • [6] Alternating Osimertinib and Gefitinib as Second-Line Treatment for EGFR-Mutated NSCLC Harbouring a T790M Resistance Mutation (OSCILLATE)
    Solomon, B.
    Mersiades, A.
    Brown, C.
    Dawson, S.
    Wong, S.
    Tan, L.
    Yip, S.
    Cheung, Y.
    Jurkovic, H.
    Walker, M.
    Kao, S.
    Lee, C. K.
    Newnham, G.
    O'Byrne, K.
    Parakh, S.
    Jasas, K.
    Bray, V.
    Stockler, M.
    John, T.
    Pavlakis, N.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S615 - S616
  • [7] EGFR T790M Mutation Detection and Osimertinib Treatment Response Evaluation by Liquid Biopsy in Advanced NSCLC Patients
    Li, C.
    Liu, H.
    Zhang, B.
    Zhang, Z.
    Su, Y.
    Wang, C.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2141 - S2142
  • [8] Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
    D Ercan
    K Zejnullahu
    K Yonesaka
    Y Xiao
    M Capelletti
    A Rogers
    E Lifshits
    A Brown
    C Lee
    J G Christensen
    D J Kwiatkowski
    J A Engelman
    P A Jänne
    Oncogene, 2010, 29 : 2346 - 2356
  • [9] Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
    Ercan, D.
    Zejnullahu, K.
    Yonesaka, K.
    Xiao, Y.
    Capelletti, M.
    Rogers, A.
    Lifshits, E.
    Brown, A.
    Lee, C.
    Christensen, J. G.
    Kwiatkowski, D. J.
    Engelman, J. A.
    Jaenne, P. A.
    ONCOGENE, 2010, 29 (16) : 2346 - 2356
  • [10] Concomitant Plasma-Genotyped T790M Positivity and Small Cell Carcinoma Transformation in EGFR-Mutated NSCLC
    Bhuniya, S.
    Mohapatra, P.
    Mishra, P.
    Patra, S.
    Panigrahi, M.
    Pradhan, G.
    Sahoo, S.
    Samal, S.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S869 - S869
12345